Literature DB >> 3675609

Is misonidazole binding to mouse tissues a measure of cellular pO2?

D J Van Os-Corby1, C J Koch, J D Chapman.   

Abstract

Misonidazole (MISO), a hypoxic cell radiosensitizer, forms covalently-linked adducts to cellular molecules as a result of bioreductive metabolism, a process which is strongly dependent upon oxygen concentration. MISO binding to liver tissue taken from air-breathing mice was three to five times greater than binding to other normal tissues. The relative binding of [14C]MISO to various mouse tissue cubes in vitro was measured by autoradiography as a function of defined oxygen concentrations, and standard curves (binding rate vs oxygen concentration) were generated. The oxygen concentration for half-maximum binding as well as the maximum and minimum binding rates (grains per 100 micron 2) observed for liver tissue were not significantly different from those measured for brain or heart tissue. These results, along with previously published data on MISO binding to isolated hepatocytes in vitro, suggest that the elevated binding to liver in vivo may result, in part, from the organ existing at a significantly lower pO2 than other normal tissues. They also suggest that this drug adduct procedure could be developed as a sensitive method for the quantitative measurement of tissue pO2 at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3675609     DOI: 10.1016/0006-2952(87)90330-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Early wound healing exhibits cytokine surge without evidence of hypoxia.

Authors:  Z A Haroon; J A Raleigh; C S Greenberg; M W Dewhirst
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Authors:  Paul D Bonnitcha; Simon R Bayly; Mark B M Theobald; Helen M Betts; Jason S Lewis; Jonathan R Dilworth
Journal:  J Inorg Biochem       Date:  2009-10-24       Impact factor: 4.155

3.  (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.

Authors:  Takuya Toyonaga; Kenji Hirata; Shigeru Yamaguchi; Kanako C Hatanaka; Sayaka Yuzawa; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Tohru Shiga; Shunsuke Terasaka; Hiroyuki Kobayashi; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-03       Impact factor: 9.236

4.  Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.

Authors:  J M Cline; D E Thrall; R L Page; A J Franko; J A Raleigh
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole.

Authors:  L M Cobb; T Hacker; J Nolan
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

6.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

Authors:  L M Cobb; J Nolan; S A Butler
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

7.  Microscopic distribution of misonidazole in mouse tissues.

Authors:  L M Cobb; J Nolan; P O'Neill
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

8.  Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells.

Authors:  M B Parliament; L I Wiebe; A J Franko
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

9.  An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.

Authors:  J A Raleigh; J K La Dine; J M Cline; D E Thrall
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

10.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver.

Authors:  G E Arteel; R G Thurman; J M Yates; J A Raleigh
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.